Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAT Neoadjuvant Regimen in Stage III Breast Cancer
NCT00128856Phase 2Completed
- Sponsor
- GEICAM
- Start
- Mar 2003
- Primary completion
- Jan 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, doxorubicin and paclitaxel in breast cancer, sponsored by GEICAM. Primary endpoint: Pathological Complete Response Rate at 15 weeks. Started Mar 2003; status: completed.
02
Drugs
gemcitabinedoxorubicinpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00128856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128856.